Abstract
Carbapenemases are a growing concern worldwide since they threaten the efficacy of carbapenems, the most potent β-lactam antibiotics. Nonmetallocarbapenemase class A (NMC-A) was identified in 1990 from a clinical isolate of Enterobacter cloacae, and since its first report in France ([1][1]), this
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
